Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(±)13-HODE cholesteryl ester was originally extracted from atherosclerotic lesions and shown to be produced by Cu2+-catalyzed oxidation of LDL. Later studies determined that 15-LO from rabbit reticulocytes and human monocytes were able to metabolize cholesteryl linoleate, a major component of LDL, to 13-HODE cholesteryl ester.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 μg | 約 35 days | ¥ 56,500 |
50 μg | 約 35 days | ¥ 107,000 |
100 μg | 約 35 days | ¥ 201,500 |
説明 | (±)13-HODE cholesteryl ester was originally extracted from atherosclerotic lesions and shown to be produced by Cu2+-catalyzed oxidation of LDL. Later studies determined that 15-LO from rabbit reticulocytes and human monocytes were able to metabolize cholesteryl linoleate, a major component of LDL, to 13-HODE cholesteryl ester. |
分子量 | 665.1 |
分子式 | C45H76O3 |
CAS No. | 167354-91-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol:PBS (1:10): <10 μg/mL
DMF: >50 mg/mL
DMSO: >50 mg/mL
Ethanol: >50 mg/mL
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
(±)13-HODE cholesteryl ester 167354-91-8 (±)13HODE cholesteryl ester 13-HODE cholesteryl ester (±)13 HODE cholesteryl ester Inhibitor inhibitor inhibit